FRAZER, Pa., Sept. 17, 2013 /PRNewswire/ -- As part of Teva Pharmaceuticals' ongoing commitment to improving the lives of people living with multiple sclerosis (MS), the company will make a $100,000 donation to the National Multiple Sclerosis Society in recognition of MS advocate, television host and film and TV producer Jack Osbourne, who has relapsing-remitting multiple sclerosis (RRMS) and is currently competing on "Dancing with the Stars." RRMS is the most common form of MS, in which a person experiences episodes of worsening neurologic functioning followed by periods of remission in which partial or complete recovery occurs.
"Teva is happy to continue our long-standing partnership with the National MS Society. Our goals align - the ongoing support of, and commitment to the MS community - and for Teva, that commitment dates back more than twenty years," said Mike Derkacz, vice president and general manager, Teva CNS. "We are proud to make this donation to the National MS Society and recognize the great work they do for people who live with MS and RRMS, like Jack Osbourne. We wish Jack well as he competes on 'Dancing with the Stars.'"
"On behalf of the National MS Society and all the people with MS that we serve, we want to thank Teva and Jack Osbourne for building awareness about MS," says Cyndi Zagieboylo, president and CEO of the National MS Society. "This donation will foster the national conversation to build greater understanding of MS, honor the spirit of all those moving their lives forward despite the challenges of MS, and support research that will one day end MS forever."
Teva is partnering with Jack Osbourne on an MS awareness campaign entitled, "You Don't Know Jack about MS," set to launch later this fall.About Jack Osbourne The youngest child of heavy metal icon Ozzy Osbourne and "The Talk" host Sharon Osbourne, Jack Osbourne is a television personality and producer of film and television projects through his production company Schweet Entertainment. Jack and his wife, Lisa Osbourne, have a daughter, Pearl, who was born in 2012 just two weeks before he was diagnosed with relapsing-remitting multiple sclerosis (RRMS), the most common form of MS. Since his diagnosis, Jack has worked as a passionate multiple sclerosis (MS) advocate, speaking out about the need for MS research and greater awareness. About Relapsing-Remitting Multiple SclerosisMultiple Sclerosis (MS) is a chronic, often disabling disease that attacks the central nervous system. Symptoms may be mild, such as numbness in the limbs, or severe, such as paralysis or loss of vision. The progress, severity, and specific symptoms of MS are unpredictable and vary from one person to another. In the U.S. today, there are approximately 400,000 people living with MS. In relapsing-remitting MS, the most common form of the disease, a person experiences attacks (also called relapses or exacerbations) of worsening neurologic functioning followed by periods of remission in which partial or complete recovery occurs. About Teva Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $20.3 billion in net revenues in 2012. Denise Bradley (215) 591-8974Nancy Leone (215) 284-0213 SOURCE Teva Pharmaceuticals
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts